NASDAQ : NBIX

Neurocrine Biosciences, Inc.

$166.8 USD

-$18.7 (-10.08%)

Volume
4.58M
Average Volume
1.28M
Market Capitalization
$16.77B
P/E Ratio
23.66
Dividend Yield
0.00%
Price Target
$200.00
Year High
$186.12
Year Low
$122.14
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.87
Company Overview

NASDAQ

Kyle W. Gano

Biotechnology

Healthcare

NBIX

2000

US

USD

https://www.neurocrine.com

858 617 7600

64125C109

0000914475

Liquidity Metrics

0.10

1.87

1.75

0.38

0.00

Sales & Valuation

$2.86B

4.97

4.22

19.27

8.62

Profitability

$4.67

$478.6M

20.91%

27.87%

20.67%

13.16%

P/E Metrics

23.66

0.23

0.23

Analyst Price Target & Rating

$200.00

$230.00

$160.00

Buy

4/5

37 Analysts

-16.60%

Financial Health Scores

9.74

5/9

$763M

$5.36B

$1.37B

$918M

Key Metrics (TTM)

$16.84B

4.99

17.91

1.87

20.67%

13.17%

4.19%

5.19%

$78.81

650 days

Company Executives
Name Title
Sanjay Keswani MBBS Chief Medical Officer
Lawrence Steinman Co-Founder of Neurocrine
Matthew C. Abernethy Chief Financial Officer
Wylie W. Vale Co-Founder
Eric S. Benevich Chief Commercial Officer
Kyle W. Gano President, CEO & Director
Lewis Choi Chief Information Officer
Jude Onyia Chief Scientific Officer
Eiry Wyn Roberts Strategic Advisor
Todd Tushla Vice President of Investor Relations
Poll Results

No votes yet today — be the first to share your view!

About Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to s ... evere pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.

NBIX Q2 Earnings Call Highlights: Portfolio Expansion Drives Growth

2026-07-31 11:02:26

Neurocrine expands its portfolio with INGREZZA, CRENESSITY and VYKAT XR growth, while advancing pipeline catalysts and commercial momentum.

Neurocrine Biosciences, Inc. (NBIX) Q2 2026 Earnings Call Transcript

2026-07-30 20:43:24

Neurocrine Biosciences, Inc. (NBIX) Q2 2026 Earnings Call Transcript

Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say

2026-07-30 18:31:02

The headline numbers for Neurocrine (NBIX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates

2026-07-30 18:16:10

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $2.85 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $1.06 per share a year ago.

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

2026-07-30 16:01:00

Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA ® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion Acquisition of Soleno Therapeutics Completed in May 2026 SAN DIEGO, July 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2026. "Our second quarter performance demonstrates the power of a strategy designed to compound over time," said Kyle W.

Neurocrine (NBIX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

2026-07-29 10:16:05

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Neurocrine (NBIX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?

2026-07-27 12:30:47

NBIX heads into Q2 results with a focus on Ingrezza sales, Crenessity growth and pipeline updates as investors watch key commercial and clinical progress.

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

2026-07-23 16:05:00

SAN DIEGO, July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team as the company executes its next phase of growth, expands its commercial portfolio and advances one of the industry's strongest neuroscience pipelines. These appointments reflect Neurocrine's continued evolution into a diversified, multi-product biopharmaceutical company positioned to deliver sustainable long-term growth.

Frequently Asked Questions

What is the current Neurocrine Biosciences, Inc. (NBIX) stock price?

Neurocrine Biosciences, Inc.(NASDAQ:NBIX) stock price is $166.8 in the last trading session. During the trading session, NBIX stock reached the peak price of $186.12 while $122.14 was the lowest point it dropped to. The percentage change in NBIX stock occurred in the recent session was --10.08% while the dollar amount for the price change in NBIX stock was -$18.7.

NBIX's industry and sector of operation?

The NASDAQ listed NBIX is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of NBIX?

Sanjay Keswani MBBS | Chief Medical Officer
Lawrence Steinman | Co-Founder of Neurocrine
Matthew C. Abernethy | Chief Financial Officer
Wylie W. Vale | Co-Founder
Eric S. Benevich | Chief Commercial Officer

How many employees does NBIX have?

Number of NBIX employees currently stands at 2000. NBIX operates from 6027 Edgewood Bend Court, San Diego, CA 92130, US.

Link for NBIX official website?

Official Website of NBIX is: https://www.neurocrine.com

How do I contact NBIX?

NBIX could be contacted at phone #858 617 7600 and can also be accessed through its website. NBIX operates from 6027 Edgewood Bend Court, San Diego, CA 92130, US.

How many shares of NBIX are traded daily?

The average number of NBIX shares traded daily for last 3 months was 1.28M.

What is the market cap of NBIX currently?

The market value of NBIX currently stands at $16.77B with its latest stock price at $166.8